2nd Next-Generation Conjugates Summit

With numerous novel conjugate companies recently receiving their INDs to enter the clinic including Avidity Biosciences and Dyne Therapeutics and many more following closely in their footsteps, conjugate drugs comprising of novel payloads and targeting formats are being thrust centre stage within the bioconjugate world.

The 2nd Next-Generation Conjugate Summit is your only platform dedicated to showcasing out-of-the-box technologies and approaches to design conjugates with novel modes of action. Furthermore, learn how to overcome key translational challenges including model selection and regulatory guidance, as well as addressing important downstream manufacturing and scale-up challenges.

Uniting 120+ thought leaders who are harnessing payloads including oligonucleotides, immune agonists, protein degraders and more, as well as novel formats including bispecifics, antibody fragments, targeted nanoparticles and bicycles; this is your opportunity to be part of exclusive discussions on expanding the application of conjugate drugs and widening their therapeutic index to progress your next-generation conjugate from bench to bedside as quickly as possible.

URLs:
Website: https://go.evvnt.com/1400588-0?pid=10018
Tickets: https://go.evvnt.com/1400588-2?pid=10018
Brochure: https://go.evvnt.com/1400588-3?pid=10018

Venue details: Hilton Boston Logan Airport, One Hotel Drive, Boston, Massachusetts, 02128, United States

Prices:
Drug Developer Pricing - Conference + Workshop Day: USD 4197.00,
Drug Developer Pricing - Conference Only: USD 2999.00,
Service Provider Pricing - Conference + Workshop Day: USD 4997.00,
Service Provider Pricing - Conference Only: USD 3599.00

Speakers: Christian Marsolais, Senior Vice President and Chief Medical Officer, Theratechnologies Inc., Fu-An Kang, Vice President, Research, MiRecule Inc., Gang Yin, Executive Director, Sutro Biopharma, Gavin Bennett, Senior Director, Program Team Leader, Bicycle Therapeutics, Giorgio Salciarini, Senior Manager, Technical Business Development, BSP Pharmaceuticals, Gregory Adams, Chief Scientific Officer, Elucida Oncology, Hanhua Huang, Vice President, Biology, Avidity Biosciences, Hans-Georg Lerchen, Chief Scientific Officer, Vincerx Pharma, Ida Lauren, PhD Student and Co-Founder, Strike Pharma, James Palacino, Vice President, Orum Therapeutics, Jarrod Longcor, Chief Operating Officer, Cellectar Biosciences, Mahendra Deonarain, Chief Executive and Science Officer, Antikor Biopharma, Marc-André Kasper, Director, Chemistry and Early Discovery, Tubulis GmbH, Michael Chansler, Vice President, Business Development, Savid Therapeutics, Niels Svenstrup, Senior Vice President, Chemistry and Manufacturing, PepGen, Oxana Beskrovnaya, Chief Scientific Officer, Dyne Therapeutics, Richard Markus, Chief Executive Officer, Dantari, Robert Huang, Founder and Chief Executive Officer, Coherent Biopharma, Sukumar Sakamuri, Chief Technology Officer, Aro Biotherapeutics, Vicky Appleman, STING Discovery Lead (Principal Scientist), Takeda Pharmaceutical Co. Ltd., Vijaya Pattabiraman, Co-Founder and Chief Technology Officer, Bright Peak Therapeutics